The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEHP.L Share News (EHP)

  • There is currently no data for EHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: AO World Surges On Strong Fourth Quarter

Thu, 31st Mar 2016 09:33

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.
----------
FTSE 100 - WINNERS
----------
TUI Group. up 6.2%. The travel operator said it will deliver growth in underlying earnings before interest, tax and amortisation in its financial year to the end of March, as it makes progress with its summer 2016 programme. TUI said winter 2015/16 is closing as expected, with 95% of the source market programme sold and increased revenue of 3% driven by higher average selling prices across most major source markets. Summer 2016 trading is also doing well, with both revenue and bookings ahead of last year, TUI said. 47% of the programme is sold so far, with revenue up 3% and bookings up 2%. It said bookings for Turkey were subdued but this was being compensated for by bookings elsewhere.

Carnival, up 1.4%. The cruise ship operator on Wednesday afternoon had said its cumulative bookings for 2016 are well ahead year-on-year as its net income and revenue grew in the first quarter of its financial year. Carnival said bookings for the rest of 2016 were higher than at the same point a year earlier and had been made at slightly higher prices.

Randgold Resources, up 1.2%. Chief Executive Mark Bristow said the gold miner is well placed to continue generating robust cash flows even at a lower gold price. Writing in the miner's annual report, Bristow said the mining industry needs to make new discoveries. A significant rise in the gold price and an injection of new capital into the industry would allow debt to be cleared, but will not provide much scope to add any value or reverse production declines. The precious metal was trading at USD1,233.20 an ounce Thursday.
----------
FTSE 100 - LOSERS
----------
BHP Billiton, down 1.9%. The mining stock went ex-dividend meaning new buyers no longer qualify for dividend payouts.
----------
FTSE 250 - WINNERS
----------
AO World, 5.7%. The online domestic appliances retailer said its UK business performed ahead of expectations in the fourth quarter of its financial year, while the European segment also performed well. AO World said UK revenue and earnings before interest, tax, depreciation and amortisation in the fourth quarter ended March 31 grew ahead of expectations, and that it now expects full-year UK revenue to be up by 19% and UK adjusted Ebitda to reach GBP17 million. Expectations for the UK business in the next financial year remain unchanged.

Serco Group, up 1.6%. The outsourcer said said the review of its joint venture contract managing the operations of the Atomic Weapons Establishment on behalf of the UK government has been concluded. Serco said the updated contract provides a framework through to 2025, with regular pricing reviews put in place. The next pricing review will take place in 2019. Serco did not provide any financial details on the deal, but said the new structure of the contract will impose greater risk-sharing on the customer, the UK Ministry of Defence, with an opportunity to earn higher margins through outperforming against the terms of the deal.

RPC Group, up 1.3%. The plastic products group said revenue and adjusted operating profit will be higher for its financial year to the end of March. RPC said revenue will be significantly higher year-on-year, benefiting from good organic sales growth and acquisition contributions.
----------
FTSE 250 - LOSERS
----------
Moneysupermarket.com Group, down 1.2%. The stock went ex-dividend.
----------
MAIN MARKET AND AIM - WINNERS
----------
GameAccount Network, up 16%. The B2B internet gaming software and content provider said it has launched a virtual reality simulated gaming application for its first continuing US client, New York's Empire City Casino. The company said the virtual reality application is compatible with both PCs and Facebook's Oculus Rift VR headsets. "Playing authentic casino games in VR for real money will dramatically close the gap between the live gaming experience available on-property and the flat two-dimensional experience available at home on traditional personal computer or mobile devices," Chief Executive Dermot Smurfit said.

Fastnet Equity, up 11%. The company said it has agreed the reverse takeover of Amryt Pharmaceuticals and will be changing its name following the deal. Fastnet said it will reverse into Amryt, an orphan drug development company, in a deal worth GBP29.6 million to be covered by the issue of 123.5 million Fastnet shares. Fastnet has sought to transition from an oil and gas company into investment company focused on the healthcare sector.
----------
MAIN MARKET AND AIM - LOSERS
----------
EpiStem Holdings, down 18%. The biotechnology firm said its pretax loss widened in the first half of its financial year on increased investment its its point-of-care device Genedrive and soft sales in its other businesses. The group said its pretax loss came in at GBP3.6 million for the six months to December 31, from GBP2.2 million the same period the previous year, after sales were down to GBP2.0 million from GBP2.2 million and discovery and development costs rose to GBP1.3 million from GBP895,000.

Nanoco Group, down 15%. The nanomaterials manufacturer said it agreed a modification of its licence agreement with US chemicals company Dow Chemical covering Nanoco's cadmium-free quantum dot technology. Under the new agreement, Dow will have non-exclusive rights for the sale, marketing and manufacture of Nanoco's quantum dot technology for use in display applications. Nanoco, will be free to pursue a range of other routes to market for its technology, giving it greater control of commercialising its intellectual property. As a result of the change to a non-exclusive agreement, Nanoco will get a lower royalty rate from Dow on Dow sales of cadmium-free dot products and will not get any earn-out income from Dow.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
7 Dec 2012 15:22

Epistem to raise 4.3m pounds via placing

Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share. The new ordinary shares, which represent 8.9% of Epistem's issued share capital have been conditionally placed with existing and new i

Read more
24 Oct 2012 15:32

Investec invests in Epistem

Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine. Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%. Earlier this month it reported steady full-year results, while d

Read more
16 Oct 2012 08:07

Epistem delivers steady performance

Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes. Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine d

Read more
6 Aug 2012 08:59

Epistem secures contract for TB test

EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts. The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis usin

Read more
5 Jul 2012 10:42

Small caps round-up: Epistem, Stadium Group, Trading Emissions

Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for Indi

Read more
11 Oct 2011 08:44

Big things expected of EpiStem's Genedrive device

Epistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year. Revenue in the year to June 30th edged up to £5.75m from £5.74m the year before, while profit on ordinary activities before ta

Read more
29 Mar 2011 13:23

Epistem sees solid growth

Adult stem cell specialist Epistem scraped into profit in the first half of its financial year. The company, which made its maiden full year profit last year, saw profit before tax in the six months to the end of December rise to £0.1m from £5,000 in the corresponding period of 2009. Revenue rose

Read more
5 Oct 2010 13:28

Maiden pre-tax profit for Epistem

UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007. The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all di

Read more
29 Jul 2010 14:16

Small caps: Titon, Utd Drug, Vernalis...

Blinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in

Read more
29 Jul 2010 07:38

Epistem FY Trading In line With Market Views, Sees Pretax Profit Up

LONDON (Dow Jones)--Epistem Holdings PLC (EHP.LN), a biotechnology company, said Thursday that trading over the year was in line with market forecasts and the company expects to report growth in year on year after tax profit. -Shares closed Wednesday at 360 pence, valuing the company at GBP28.36

Read more
9 Mar 2010 12:03

EpiStem breaks even as revenue soars

The Novel Therapies division is threatening to steal the show at epithelial stem cells specialist Epistem, as the benefits of its transformational deal with Swiss pharmaceutical giant Novartis kicks in. The UK biotechnology company saw revenue soar 90% in 2009 almost entirely as a result of the co

Read more
9 Nov 2009 11:43

Small caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...

Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage. Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year. Shares in e-learn

Read more
12 Oct 2009 17:18

Douglas sure about Shore

Shares in stockbroker Shore Capital have almost tripled in value since April, but non-executive director Barclay Douglas thinks there's more to come. The accountant has spent £92,000 on 250,000 shares at 36.75p each. He now owns 1.25m shares, or half a per cent of the company. Shore received a sho

Read more
6 Oct 2009 11:37

Update: Epistem benefits from raised profile

Drug testing group Epistem moved closer to profit after a research and collaboration deal with the Swiss pharmaceutical giant Novartis helped revenues soar. The firm posted a pre-tax loss of £700,000 in the year to June 30 compared with losses of £1.3m previously, with revenues nearly doubling to £

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.